Research programme: cytomegalovirus vector based immunotherapeutics - UbiVac

Drug Profile

Research programme: cytomegalovirus vector based immunotherapeutics - UbiVac

Alternative Names: CMV replication deficient vaccine - UbiVac; sdCMV 001; sdCMV 002

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UbiVac
  • Developer Oregon Health & Science University; UbiVac
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Human papillomavirus infections; Malignant melanoma

Most Recent Events

  • 28 Oct 2015 Preclinical trials in Cancer in USA (parenteral) before October 2015 (UbiVac pipeline, October 2015)
  • 28 Oct 2015 Preclinical trials in Human papillomavirus infections in USA (parenteral) (UbiVac pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top